TALAPRO-2 Talazoparib Plus Enzalutamide Improves Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer – The ASCO Post

TALAPRO-2 – talazoparib + enzalutamide improves progression free survival for men with mCRPC. No data on Overall survival yet. Benefit seen for men with HRD mutations and those without (although greater in those with HRD mutations). Nearly three quarters of men in combination arm had side effects.

Read the full article here

Related Articles